NCT03063892
Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion
Active, Not Recruiting
PHASE4Ages 60+InterventionalTreatmentGregory M Georgiadis MDInvestigator-initiated
~200 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Tranexamic Acid (TXA)Saline solution
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
proportion of patients requiring packed Red Blood Cell transfusion
Measured over 72 hours
Conditions
Where it's being run
1 sites across 1 statesOhio1
Study leadership
- Gregory M Georgiadis, MD · PRINCIPAL_INVESTIGATOR · ProMedica Toledo Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Over the age of 60 years
Hip fracture requiring surgical intervention
Signs consent and agrees to participate
Exclusion
Under the age of 60
Does not sign consent or refuses participation
Known hypersensitivity to tranexamic acid
Multiple acute fractures
Creatinine clearance \<30
History of seizures
Active hormone therapy
History of coagulation abnormality
History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE
Myocardial infarction (MI) and/or stents within the past year
History of intracranial hemorrhage
Acquired defective color vision
Patients admitted directly to nursing units or surgery without stay in the Emergency Center
Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital
What this trial measures
- proportion of patients requiring packed Red Blood Cell transfusion72 hours
units, perioperative